Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Pharmaceutical Group Sues US Government Over Medicare Drug Pricing Rule

Pharmaceutical Group Sues US Government Over Medicare Drug Pricing Rule

MT newswireMT newswire2026/10/07 17:43

01:43 PM EDT, 10/07/2026 (MT Newswires) -- The Pharmaceutical Research and Manufacturers of America said Wednesday it filed a lawsuit against the US government seeking to vacate Medicare's most favored nation drug pricing policy, alleging that it is unlawful and exceeds Centers for Medicare & Medicaid Services' authority. The complaint filed in the US District Court for the District of Columbia challenges the GLOBE rule, which requires drug manufacturers to pay rebates to the CMS that effectively limit Medicare Part B drug prices to benchmarks based on prices in 19 OECD countries, according to a statement. The group said the rule would provide minimal patient benefit, with only 0.3% of Medicare Part B beneficiaries expected to benefit from lower out-of-pocket costs, and could reduce investment in research and development. The group argued that the policy imposes nationwide price-setting policies without congressional authorization and raises constitutional concerns. The Department of Health and Human Services did not immediately respond to MT Newswires' request for comment. Price: 142.80, Change: +0.86, Percent Change: +0.61

01:43 PM EDT, 10/07/2026 (MT Newswires) -- The Pharmaceutical Research and Manufacturers of America said Wednesday it filed a lawsuit against the US government seeking to vacate Medicare's most favored nation drug pricing policy, alleging that it is unlawful and exceeds Centers for Medicare & Medicaid Services' authority. The complaint filed in the US District Court for the District of Columbia challenges the GLOBE rule, which requires drug manufacturers to pay rebates to the CMS that effectively limit Medicare Part B drug prices to benchmarks based on prices in 19 OECD countries, according to a statement. The group said the rule would provide minimal patient benefit, with only 0.3% of Medicare Part B beneficiaries expected to benefit from lower out-of-pocket costs, and could reduce investment in research and development. The group argued that the policy imposes nationwide price-setting policies without congressional authorization and raises constitutional concerns. The Department of Health and Human Services did not immediately respond to MT Newswires' request for comment. Price: 142.80, Change: +0.86, Percent Change: +0.61
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Cold wave and rising fuel costs drive electricity prices in northeastern Japan and Tokyo to a four-year high

Japan's spot electricity prices surged to multi-year highs over the weekend.

智通财经•2026/11/09 08:07
Cold wave and rising fuel costs drive electricity prices in northeastern Japan and Tokyo to a four-year high

Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail

Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.

智通财经•2026/11/09 07:32
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail